Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer

被引:136
作者
Joly, F.
Alibhai, S. M. H.
Galica, J.
Park, A.
Yi, Q. -L.
Wagner, L.
Tannock, I. F.
机构
[1] Ctr Francois Baclesse, Dept Med Oncol, F-14076 Caen, France
[2] Univ Toronto, Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[3] Northwestern Univ, Sch Med, Evanston, IL 60208 USA
关键词
neoplasm metastasis; prostatic neoplasms; quality of life; cognition; SUPPRESSION; FATIGUE;
D O I
10.1016/j.juro.2006.07.151
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Many patients with prostate cancer receive androgen deprivation therapy for long periods. We compared physical and cognitive function, and quality of life in a cross-sectional study of 57 patients receiving androgen deprivation therapy for nonmetastatic prostate cancer and 51 healthy age matched controls. Materials and Methods: Physical and daily function were measured by the 6-minute walk test, grip strength, the timed up and go test, and activities of daily living measures. Cognitive function was evaluated by the High Sensitivity Cognitive Screen and by a self-report prototype Functional Assessment of Cancer Therapy cognitive function subscale. Quality of life was assessed by the Functional Assessment of Cancer Therapy-General with the subscale for fatigue and by the Patient-Oriented Prostate Utility Scale. Results: Androgen deprivation therapy was given for a median of 1.8 years (range 0.4 to 7.4). Patients had lower median hemoglobin than controls (134 vs 148 gm/l, p < 0.0001). Performance on physical tests was similar in the 2 groups. Moderate or severe cognitive impairment by the High Sensitivity Cognitive Screen was similar for patients (23%) and controls (35%, p = 0.2). Self-reported cognitive dysfunction was also similar. Scores for the Functional Assessment of Cancer TherapyGeneral were similar but the Patient Oriented Prostate Utility Scale summary score was worse for patients (median 71 vs 86, p < 0.001). More patients reported severe fatigue (Functional Assessment of Cancer Therapy-Fatigue score less than 35, p = 0.03). Low energy, poor bladder control and loss of sexual function were reported in 36%, 47% and 95% of patients, and in 16%, 34% and 33% of controls, respectively. Conclusions: Patients treated with androgen deprivation therapy experience more symptoms and have worse fatigue than controls, but this study did not detect any effect on physical or cognitive function.
引用
收藏
页码:2443 / 2447
页数:5
相关论文
共 21 条
[1]   Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial [J].
Bolla, M ;
Collette, L ;
Blank, L ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Mattelaer, J ;
Torecilla, JL ;
Pfeffer, JR ;
Cutajar, CL ;
Zurlo, A ;
Pierart, M .
LANCET, 2002, 360 (9327) :103-108
[2]   2-MINUTE, 6-MINUTE, AND 12-MINUTE WALKING TESTS IN RESPIRATORY-DISEASE [J].
BUTLAND, RJA ;
PANG, J ;
GROSS, ER ;
WOODCOCK, AA ;
GEDDES, DM .
BRITISH MEDICAL JOURNAL, 1982, 284 (6329) :1607-1608
[3]   Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of cancer therapy (FACT) anemia and fatigue scales [J].
Cella, D ;
Eton, DT ;
Lai, JS ;
Peterman, AH ;
Merkel, DE .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 24 (06) :547-561
[4]   Complications of androgen-deprivation therapy in men with prostate cancer [J].
Chen A.C. ;
Petrylak D.P. .
Current Urology Reports, 2005, 6 (3) :210-216
[5]   The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer [J].
Cherrier, MM ;
Rose, AL ;
Higano, C .
JOURNAL OF UROLOGY, 2003, 170 (05) :1808-1811
[6]  
Descazeaud A, 2004, PROG UROL, V14, P1177
[7]  
Fogel B S, 1991, Int Psychogeriatr, V3, P273, DOI 10.1017/S1041610291000728
[8]   Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial [J].
Green, HJ ;
Pakenham, KI ;
Headley, BC ;
Yaxley, J ;
Nicol, DL ;
Mactaggart, PN ;
Swanson, C ;
Watson, RB ;
Gardiner, RA .
BJU INTERNATIONAL, 2002, 90 (04) :427-432
[9]   Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial [J].
Green, HJ ;
Pakenham, KI ;
Headley, BC ;
Yaxley, J ;
Nicol, DL ;
Mactaggart, PN ;
Swanson, CE ;
Watson, RB ;
Gardiner, RA .
BJU INTERNATIONAL, 2004, 93 (07) :975-979
[10]   Complications of androgen deprivation therapy for prostate cancer [J].
Holzbeierlein, JM ;
McLaughlin, MD ;
Thrasher, JB .
CURRENT OPINION IN UROLOGY, 2004, 14 (03) :177-183